Cancer is clearly a genetic disease, as demonstrated by the complexity of cancer genomes that can carry hundreds of mutations in oncogenes and tumor suppressor genes, collectively known as cancer ...

We evaluate cancer-protective effects of walnuts via formation of microbe-derived urolithin A, substantiating their functional benefits on serum inflammatory markers and immunologic composition of ...

Mutations in ERBB2 (encoding HER2) occur in 2% to 4% of non–small cell lung cancer (NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for treating other ...

The 5-year survival rate for pancreatic ductal adenocarcinoma (PDA) is currently 13%, making it one of the most fatal human malignancies; to date, PDA is the third leading cause of cancer-related ...

EMERALD, an open-label phase III trial, randomly assigned patients with ER +, HER2 − metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to ...

Endocrine therapies (ET) with cyclin-dependent kinase 4/6 (CDK4/6) inhibition are the standard treatment for estrogen receptor-α-positive (ER +) breast cancer, however drug resistance is common. In ...

In a previous study (12), murine IL2 and IL12 were separately fused to collagen-binding domains to promote retention in the tumor by anchoring the cytokines to collagen, which is in high abundance in ...

The DIANA-5 study involved 1,542 patients with breast cancer at high risk of recurrence because of estrogen receptor–negative cancer, or metabolic syndrome, or high plasma levels of insulin or ...

Peposertib—an orally administered DNA-dependent protein kinase inhibitor—has shown potent radiosensitization in preclinical models. This dose-escalation study (NCT03770689) aimed to define the maximum ...

Clinical resistance to immunotherapy is common in breast cancer, and many patients will likely require combination therapy to maximize immunotherapeutic benefit. This study demonstrates that ...

AbstractPurpose:. Cachexia is common in patients with advanced cancer and is associated with elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), ...